KFP H015
Alternative Names: H 015; KFP-H015Latest Information Update: 06 Oct 2021
Price :
$50 *
At a glance
- Originator Jiangsu Carephar Pharmaceutical
- Class Antivirals
- Mechanism of Action Endonuclease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Viral infections
Most Recent Events
- 28 Sep 2021 Jiangsu Carephar Pharmaceutical has patent pending related to KFP H015 in China (Jiangsu Carephar Pharmaceutical website, September 2021)
- 28 Sep 2021 Preclinical trials in Viral infections in China (unspecified route) before September 2021 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)
- 28 Sep 2021 Jiangsu Carephar Pharmaceutical plans to submit IND application for Viral infections in USA and China in 2022 (Jiangsu Carephar Pharmaceutical pipeline, September 2022)